Aspen Neuroscience Secures $115M Series C Funding

Why It Matters

The infusion of $115 million accelerates development of a potentially disease‑modifying Parkinson’s treatment, positioning Aspen as a frontrunner in personalized regenerative therapy and attracting further biotech investment in the neuro‑degeneration space.

Deal Summary

Aspen Neuroscience announced the closing of a $115 million Series C round to advance its autologous regenerative therapies for Parkinson's disease. The round was co‑led by OrbiMed, ARCH Venture Partners, Frazier Life Sciences and Revelation Partners, with participation from existing and new investors.